Regs.gov: Drug Enforcement Administration

P2P Methyl Glycidic Acid Control as List I Chemical

The Drug Enforcement Administration finalized control of P2P methyl glycidic acid (2-methyl-3-phenyloxirane-2-carboxylic acid, also known as BMK glycidic acid) as a List I chemical under the Controlled Substances Act. This action subjects all handlers of this precursor chemical to CSA regulatory requirements including registration, recordkeeping, and reporting obligations. The rule takes effect May 4, 2026.

DEA Controlled Substance Prescription Rule Correction

The Drug Enforcement Administration issued a correction to 21 CFR § 1306.07, fixing paragraph letter references in amendatory instruction 15 from '(e)' and '(f)' to '(g)' and '(h)'. This technical correction to the controlled substance prescribing rule affects entities regulated under DEA's multiple prescription provisions.

3-Methoxyphencyclidine Placed in Schedule I

The Drug Enforcement Administration has issued a final rule placing 3-methoxyphencyclidine (3-MeO-PCP) in Schedule I of the Controlled Substances Act. This action enables the United States to meet its obligations under the 1971 Convention on Psychotropic Substances following the Commission on Narcotic Drugs' Decision 64/4. All persons handling 3-MeO-PCP will be subject to regulatory controls and administrative, civil, and criminal sanctions applicable to Schedule I controlled substances.

Technical Amendment to DEA Form 222 Power of Attorney Provisions

DEA issued a final rule correcting 21 CFR 1305.05(c) and (e) to align with the 2019 amendment at 21 CFR 1305.05(d)(1). The technical amendment clarifies that only a registrant, partner, or officer may execute or revoke a DEA Form 222 Power of Attorney, resolving ambiguities from an administrative error. The rule also removes obsolete transition provisions for the triplicate version of DEA Form 222.

Temporary Scheduling of Bromazolam as Schedule I Controlled Substance

The DEA issued a temporary scheduling order placing bromazolam (8-bromo-1-methyl-6-phenyl-4H-benzo[f][1,2,4]triazolo[4,3-a][1,4]diazepine) in Schedule I of the Controlled Substances Act. The order is effective March 16, 2026, and will remain in effect until March 16, 2028. DEA determined that bromazolam poses an imminent hazard to public safety, triggering the temporary scheduling authority under 21 U.S.C. 811(h).

DEA Designates P2P Methyl Glycidic Acid as List I Chemical

The Drug Enforcement Administration has finalized the designation of P2P methyl glycidic acid (2-methyl-3-phenyloxirane-2-carboxylic acid) and its esters, isomers, and salts as a List I chemical under the Controlled Substances Act, effective May 4, 2026. This chemical is used in the illicit manufacture of phenylacetone, methamphetamine, and amphetamine. All handlers must obtain DEA registration and comply with CSA regulatory provisions, including transaction reporting and recordkeeping requirements.

Controlled Substance Importer Registration Application - MDMA

The DEA published notice that Fisher Clinical Services, Inc. applied on March 11, 2026 to be registered as an importer of 3,4-Methylenedioxy-methamphetamine (MDMA, Schedule I, drug code 7405) for clinical trials only. The company is located in Allentown, Pennsylvania. Registered bulk manufacturers and applicants may submit comments or objections, or request a hearing, by May 1, 2026.

Controlled Substances Importer Application - Research Triangle Institute

DEA published notice that Research Triangle Institute (Durham, NC) applied to be registered as an importer of controlled substances for 30 Schedule I drug classes including synthetic cathinones, benzodiazepine analogs, and other psychoactive substances. The application was filed March 3, 2026. Interested parties may submit comments or request hearings on the application through May 1, 2026.

Controlled Substance Importer Registration Application - Sterling Wisconsin LLC

The Drug Enforcement Administration published notice that Sterling Wisconsin, LLC applied for registration as a Schedule I controlled substance importer (drug code 7431 - 5-Methoxy-N,N-dimethyltryptamine). The application was filed January 27, 2026. Interested parties may submit comments or hearing requests by May 1, 2026.

Indivior Manufacturing LLC - Controlled Substances Importer Registration Application

The DEA published notice that Indivior Manufacturing LLC applied on February 26, 2026, to be registered as an importer of Thebaine (drug code 9333, Schedule II controlled substance). The company plans to import limited quantities for research, clinical trials, analytical purposes, and manufacturing process development of dosage forms. The public comment period closes on May 1, 2026.